SK pharmteco

SK pharmteco announced today a more than $200 million investment in our U.S. operations, expanding development and manufacturing capacity across our small molecule and peptide capabilities. The comprehensive five-year investment plan will support new development laboratories, GMP kilo-scale peptide capacity, advanced purification capabilities, expanded manufacturing suites, and upgraded infrastructure and digital technologies. The investment is expected to create approximately 100 long-term, high-skilled jobs while strengthening U.S. capabilities across API, peptide, and advanced therapy supply. This investment reflects our commitment to building a stronger, more reliable foundation for our customers and the medicines they are working to bring to patients. Read the full press release: https://lnkd.in/eQpE9d7g/?utm_campaign=Small_Molecule_TOF&utm_source=linkedin&utm_medium=paid&utm_id=1186153216&hsa_acc=512390435&hsa_cam=1186153216&hsa_grp=860660426&hsa_ad=1632222076&hsa_net=linkedin&hsa_ver=3

Introducing: the SK pharmteco Catalyst Kit. A structured pathway for moving catalytic reaction development from initial catalyst screening through process optimization and commercial-scale continuous manufacturing. The Catalyst Kit follows a three-step approach to move catalytic reaction development from initial screening through optimization and commercial-scale manufacturing. It begins by evaluating 12 catalysts to identify promising candidates, then refines catalyst composition and process conditions to improve performance, and finally transfers optimized conditions from lab scale through kilo, pilot, and full-scale GMP commercial manufacturing. The Catalyst Kit brings together SK pharmteco’s expertise in catalyst design, development, optimization, and continuous processing to support catalytic processes for RSMs, intermediates, and APIs. Screen to identify. Optimize to perform. Scale with confidence. Read the full press release here: https://lnkd.in/eMn2H8zp/?utm_campaign=Small_Molecule_TOF&utm_source=linkedin&utm_medium=paid&utm_id=1186153216&hsa_acc=512390435&hsa_cam=1186153216&hsa_grp=907931826&hsa_ad=1632194996&hsa_net=linkedin&hsa_ver=3

We are honored to be a part of an important clinical milestone for GEMMA Biotherapeutics and the Spinal Muscular Atrophy Type 1 (SMA1) community as the first patient has been dosed in GEMMABio’s CHARISMA Phase 1/2 clinical trial, evaluating GB221, an investigational next-generation gene therapy for SMA1. SK pharmteco is supplying critical clinical trial materials for the study, supporting GEMMABio’s evaluation of a targeted approach to gene therapy delivery directly into the central nervous system. This is the beginning of a broader collaboration. Beyond the ongoing SMA1 program, we are planning additional manufacturing collaborations across GEMMABio’s rare disease pipeline, including future programs expected to leverage our SKyvec™ viral vector platform. For rare disease programs, every step matters. We’re proud to contribute the manufacturing expertise and capabilities that help move promising genetic medicines from the lab toward the patients who need them Read the full announcement: https://lnkd.in/e-_4HfCh

Solvent recovery, reuse, and recycling can help pharmaceutical manufacturers reduce virgin solvent use, minimize waste and strengthen supply-chain resilience. But making it work at scale takes more than choosing a technology. Join us on October 1 for a practical look at how to identify and implement solvent recovery strategies across the pharmaceutical lifecycle. 🔸 Explore technologies including distillation, evaporation, PAT, chromatography and melt crystallization 🔸 See real-world case studies across API, continuous chromatography and oligonucleotide manufacturing 🔸 Learn how solvent recovery can support sustainability goals while balancing quality, safety, energy, economics and supply Solvent Recovery Systems for Sustainable Pharmaceutical Manufacturing 📅 October 1, 2026 🕚 11:00 AM EST 👉 Register here: https://lnkd.in/eBmPnpin/?utm_campaign=Small_Molecule_TOF&utm_source=linkedin&utm_medium=paid&utm_id=1186153216&hsa_acc=512390435&hsa_cam=1186153216&hsa_grp=860660426&hsa_ad=1621221776&hsa_net=linkedin&hsa_ver=3

Where does solvent recovery make sense in pharmaceutical manufacturing, and what does it take to implement it successfully? Join us October 1 to explore how SK pharmteco approaches solvent recovery in practice, with real-world case studies in commercial API manufacturing, continuous chromatography, and oligonucleotide production. Explore practical ways to reduce solvent use, waste, and supply-chain risk. ⏩Register for the webinar.

When you’re ready to scale your API, you need more than capacity. SK pharmteco supports APIs, intermediates and HPAPIs from clinical to commercial scale.